University of Vermont

College of Medicine

Department of Medicine

Nephrology

clinical trials

Clinical Trials

Status: Active - Recruiting
Observational Study in Patients with Autosomal Dominant Polycystic Kidney Disease (OVERTURE)
Purpose: To collect characteristics of patients with ADPKD across a broad population, over time to better understand disease progression (signs, symptoms and outcomes). Association with total kidney volume changes and other measures of disease progression will be determined in order to identify a population at increased risk for disease progression. The economic and quality life impact of ADPKD will be assessed. Subjects who terminated participation early from clinical trials with tolvaptan may also be followed.
ClinicalTrials.gov Identifier: NCT01430494
Primary/Site/Co Investigator: Wolfgang J. Weise, M.D.
Contact: Patricia Murray, R.N., 802-847-4095
Information on this trial: Clinicaltrials.gov
Status: Active - Recruiting
Evaluation of Sodium Bicarbonate to Reduce the Incidence of Contrast Induced Chronic Kidney Injury in Patients With Kidney Disease (BOSS)
Purpose: Patients with Stage 3B, 4,or 5 Chronic Kidney Disease who are to undergo an angiography procedure with contrast agent will be asked if they are willing to join the trial. If so they will be screened and randomized to receive either sodium bicarbonate or saline before, during and after the contrast media is given. They will be asked for serum samples 1 to 3 days, 7, 30, 90 and 180 days after the procedure to evaluate whether the sodium bicarbonate has reduced the incidence of contrast induced chronic kidney disease by measuring their serum creatinine, as well as whether they have required renal dialysis or other renal replacement therapy.
Primary/Site/Co Investigator: Richard Solomon, M.D.
Contact: Patricia Murray, R.N., 802-847-4095
Information on this trial: Clinicaltrials.gov
Status: Active - Recruiting
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes (BEACON)
Purpose: This study assesses the efficacy of bardoxolone methyl relative to placebo in delaying progression to end-stage renal disease (ESRD) and cardiovascular deaths in patients with Stage 4 Chronic Kidney Disease (CKD) and type 2 diabetes receiving standard of care.
ClinicalTrials.gov Identifier: NCT01351675
Primary/Site/Co Investigator: Richard Solomon, M.D.
Contact: Patricia Murray, R.N., 802-847-4095
Information on this trial: Clinicaltrials.gov
Status: Active - Recruiting
Renal Denervation in Patients With Uncontrolled Hypertension (SYMPLICITY HTN-3)
Purpose: The Symplicity HTN-3 study is a, multi-center, prospective, single-blind, randomized, controlled study of the safety and effectiveness of renal denervation in subjects with uncontrolled hypertension. Bilateral renal denervation will be performed using the Symplicity Catheter - a percutaneous system that delivers radiofrequency (RF)energy through the luminal surface of the renal artery.
ClinicalTrials.gov Identifier: NCT01418261
Primary/Site/Co Investigator: Richard Solomon, M.D.
Contact: Patricia Murray, R.N., 802-847-4095
Information on this trial: Clinicaltrials.gov
Status: Active - Not Yet Recruiting
FAHC Studyof Renal CT Findings 24 Hours Post Coronary Angiography
Purpose: pending
ClinicalTrials.gov Identifier: tbd
Primary/Site/Co Investigator: Richard Solomon, M.D.
Contact: Patricia Murray, R.N., 802-847-4095
Information on this trial: pending
Status: Active - Not Recruiting
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Purpose: This trial is a three-period, multicenter, safety and efficacy clinical trial. The first period is a two-week Washout Period, the second period is a 52-week randomized, open-label, active control Safety Assessment Period, and the third period is a four-week, randomized, open-label, placebo-controlled Efficacy Assessment Period in only the patients who were randomized to treatment with ferric citrate during the Safety Assessment Period. The primary objectives of this trial are to determine the long-term safety over 52 weeks of up to twelve (12) caplets/day of KRX-0502 (ferric citrate) in patients with ESRD undergoing either hemodialysis or peritoneal dialysis and to determine the efficacy of KRX-0502 (ferric citrate) in the four-week, randomized, open-label, placebo-controlled Efficacy Assessment Period.
ClinicalTrials.gov Identifier: NCT01191255
Primary/Site/Co Investigator: Dana Negoi, M.D.
Contact: Patricia Murray, R.N., 802-847-4095
Information on this trial: Clinicaltrials.gov
Status: Active - Not Recruiting
E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events
Purpose: The purpose of this study is to evaluate the effects of cinacalcet (cinacalcet HCl or Sensipar®/Mimpara®) on cardiovascular events and death in chronic kidney disease (CKD) patients with secondary hyperparathyroidism (HPT) who are receiving dialysis.
ClinicalTrials.gov Identifier: NCT00345839
Primary/Site/Co Investigator: Wolfgang Weise, M.D.
Contact: Patricia Murray, R.N., 802-847-4095
Information on this trial: Clinicaltrials.gov
Status: Active - Not Recruiting
FAHC Quality Improvement Project with Cardiothoracic Surgery to Minimize AKI post CABG
Purpose: pending
ClinicalTrials.gov Identifier: tbd
Primary/Site/Co Investigator: Richard Solomon, M.D.
Contact: Patricia Murray, R.N., 802-847-4095
Information on this trial: pending
Status: Active - Not Recruiting
Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions (CORAL)
Purpose: This study will compare medical therapy plus stenting of hemodynamically significant renal artery stenoses versus medical therapy alone in patients with systolic hypertension and renal artery stenosis.
ClinicalTrials.gov Identifier: NCT00081731
Primary/Site/Co Investigator: Richard Solomon, M.D./Jeffrey Rimmer, M.D.
Contact: Patricia Murray, R.N., 802-847-4095
Information on this trial: Clinicaltrials.gov
Status: Enrollment Closed
Aliskiren Trial in Type 2 Diabetes Using Cardovasclar and Renal Disease Endpoints (ALTITUDE)
Purpose: The purpose of this study is to determine whether, in patients with type 2 diabetes and pre-existing disease of the heart and the circulatory system and/or the kidney, aliskiren at a target dose of 300 mg once daily (compared to placebo), on top of conventional treatment, reduces death and disease caused by the heart, the circulatory system and the kidney.
ClinicalTrials.gov Identifier: NCT00549757
Primary/Site/Co Investigator: Richard Solomon, M.D.
Contact: Patricia Murray, R.N., 802-847-4095
Information on this trial: Clinicaltrials.gov
Status: Not Active - Not Recruiting
Blood Pressure Monitoring Program Quality Improvement Project
Purpose: To increase the percent of people with CKD attending renal clinic who have BP at goal by encouraging patient participation in their care
ClinicalTrials.gov Identifier: tbd
Primary/Site/Co Investigator: Virginia Hood, M.D., M.B.B.S
Contact: Suzanne Lapointe, R.N., 802-847-3572
Information on this trial: All patients who attend the Nephrology Clinic can participate

Last modified April 17 2012 03:09 PM